ResMed (RMD) has become the subject of valuation scrutiny on the ASX, with an Australian investment outlet presenting a case for potential undervaluation. The analysis appears to frame the company's current pricing relative to fundamental metrics, suggesting market inefficiency in how the medical device and cloud software provider is being priced by regional investors.
ResMed's dual exposure—spanning respiratory care devices and cloud-based care coordination software—provides defensive characteristics in health care while maintaining growth optionality in digital health. The valuation conversation likely centers on earnings yield relative to sector peers and the company's recurring revenue streams from software-as-a-service operations, which provide predictable cash flows and pricing power.
A bullish thesis on RMD shares hinges on market underappreciation of either the company's software segment growth trajectory or near-term earnings trajectory relative to its trading multiple. The ASX listing attracts a different investor base than the US-listed parent, potentially creating pricing inefficiencies between markets.
Sector implication: A reassessment of RMD valuation would strengthen conviction in Health Care sector rotation, particularly in companies blending capital-light software models with stable device revenue. This signals investor appetite for non-pharmaceutical health care exposure with recurring revenue characteristics.